Earnings Releases·Nov 13, 2026, 5:27 PM ET

Tempest Therapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $3.6 million ($0.21 per share) for the quarter, an improvement from $3.5 million ($0.79 per share) in the prior year period, while nine-month net loss widened to $36.6 million ($2.54 per share) from $22.2 million ($5.71 per share) due to $22.2 million in acquired in-process research and development expenses.
Cash and cash equivalents declined to $0.9 million from $7.7 million at year-end 2025, with the company stating existing cash funds operations for less than 12 months and expressing substantial doubt regarding its ability to continue as a going concern.
Secured exclusive global rights (excluding China) to Senlang's CD7-targeted in vivo CAR-T platform and unveiled candidate TPST-4003, while initiating a Phase 1 study for lead candidate TPST-4903 with preliminary data expected soon and a China trial for TPST-4003 scheduled for Q4 2026.
Raised approximately $1.8 million net from a September private placement of warrants and entered a $25 million (potentially $50 million) equity line with Lincoln Park Capital, selling $0.3 million of stock through the line by quarter-end.
Operating expenses reflected strategic shifts with R&D costs dropping to $0.2 million for the quarter from $0.6 million in the prior year, driven by portfolio re-prioritization following a February 2026 asset acquisition, though G&A expenses rose to $11.5 million for the nine months due to one-time transaction costs.